Wilson's disease: The importance of measuring serum caeruloplasmin non-immunologically

Annals of Clinical Biochemistry

Volumn 40, Issue 2, 2003, Pages 115-121

  Walshe, J M ^a,b,c  

^a MIDDLESEX HOSPITAL   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c Broom Lodge   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; CERULOPLASMIN; CHELATING AGENT; COPPER; DIMERCAPROL; OXIDOREDUCTASE; PENICILLAMINE; TETRATHIOMOLYBDIC ACID; TRIENTINE; ZINC;

ANEMIA; BLOOD TOXICITY; BONE MARROW DEPRESSION; CALCULATION; CERULOPLASMIN BLOOD LEVEL; CHROMOSOME 13Q; CLINICAL FEATURE; COPPER BLOOD LEVEL; DIAGNOSTIC TEST; DRUG EFFICACY; ENZYME ACTIVITY; ERYTHROCYTE SEDIMENTATION RATE; FOLLOW UP; GENE IDENTIFICATION; GENETIC ANALYSIS; HEMOLYSIS; HUMAN; IRON DEFICIENCY ANEMIA; LIVER FUNCTION TEST; LIVER INJURY; MOTOR SYSTEM; NEPHELOMETRY; NEPHRITIS; NEPHROTOXICITY; NEUROLOGIC DISEASE; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROTEIN URINE LEVEL; REVIEW; SCREENING TEST; SIDE EFFECT; SIDEROBLASTIC ANEMIA; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; URINE LEVEL; WILSON DISEASE;

CERULOPLASMIN; CHEMISTRY, CLINICAL; COPPER; FEMALE; HEPATOLENTICULAR DEGENERATION; HUMANS; MALE; MICROSATELLITE REPEATS; OXIDOREDUCTASES; PEDIGREE;

EID: 0037350153     PISSN: 00045632     EISSN: None     Source Type: Journal    
DOI: 10.1258/000456303763046021     Document Type: Review

References (35)

1. Walshe JM, Yealland M. Wilson's disease: the problem of delayed diagnosis. J Neurol Neurosurg Psychiatry 1992; 55: 692-6
2. Scheinberg IH, Sternlieb I. Wilson's disease. In: Smith LH ed. Major Problems in Internal Medicine, Vol. XXIII. Philadelphia: WB Saunders, 1984
3. Walshe JM. The eye in Wilson's disease. In: Bergsma D, Bron AJ, Cotlier E, eds. The Eye and Inborn Errors of Metabolism [Birth Defects: Original Article Series Vol. XII, No. 3]. New York: National Foundation - March of Dimes, 1976: 187-9
4. Bachmann H, Lossner J, Grub B, Rucholz V. Die Epidemiologie der Wilsonchen Erkrankung in der DDR and die derzeitige Problematik einer populationgenetischen Bearbeitung. Psychiatr Neurol Med Psychol 1979; 30: 393-400
5. Thomas GR, Forbes JR, Roberts EA, Walshe JM, Cox DW. The Wilson's disease gene: spectrum of mutations and their consequences. Nat Genet 1995; 9: 210-7
6. Cox DW. Disorders of copper transport. Br Med Bulletin 1999;55:544-55
7. Waldenstrom E, Lagerkvist A, Dahlman T, Westermark K, Landgren U. Efficient detection of mutations in Wilson disease by manifold sequencing. Genomics 1996; 30: 303-9
8. Farrer LA, Bowcock AM, Hebert JM, Bonne-Tamir B, Sternlieb I, Giagheddu MD, et al. Predictive testing for Wilson's disease using tightly linked and flanking DNA markers. Neurology 1991; 41: 992-9
9. Gibbs K, Hanka R, Walshe JM The urinary excretion of radiocopper in pre-symptomatic and symptomatic Wilson's disease, heterozygotes and controls: its significance in diagnosis and management. Q J Med 1978; 47: 349-64
10. 64Cu) in Wilson's disease and various control groups. Q J Med 1977; 46: 445-62
11. Magdoff-Fairchild B, Lovell FM, Low BW. An X-ray crystallographic study of ceruloplasmin. Determination of molecular weight. J Biol Chem 1969; 244: 3497-9
12. Walshe JM. Studies on the oxidase properties of ceruloplasmin: factors in normal and Wilson's disease serum affecting oxidase activity. J Clin Invest 1963; 412: 1048-53
13. Sato M, Hachiya N, Yamaguchi Y, Jubota J, Saito Y, Fujioka Y, et al. Deficiency of holo- but not apo-ceruloplasmin in genetically intoxicated LEC mutant rats. Life Sci 1993; 53: 1411-6
14. Gibbs K, Walshe JM. A study of caeruloplasmin concentrations found in 75 patients with Wilson's disease, their kinships and various control groups. Q J Med 1979; 48: 447-63
15. Walshe JM, Briggs J. Caeruloplasmin in liver disease. Lancet 1962; ii: 263-5
16. Logan JI, Harveyson KB, Wisdom GB, Hughes AE, Archbold GPR. Hereditary caeruloplasmin deficiency, dementia and diabetes mellitus. Q J Med 1994; 87: 663-87
17. Walshe JM. Wilson's disease (hepatolenticular degeneration). In: Haubrich WS, Schaffner F, Berk JE, eds. Bockus Gastroenterology, 5th edn. Philadelphia: WB Saunders, 1995: 2340-51
18. Goldfischer S, Sternlieb I. Changes in the distribution of hepatic copper in relation to the progression of Wilson's disease (hepatolenticular degeneration). Am J Pathol 1968; 53: 883-91
19. Sternlieb I, Morell AG, Bauer CD, De Bobbes-Sternberg S, Scheinberg IH. Detection of the heterozygous carrier of the Wilson's disease gene. J Clin Invest 1961; 40: 707-15
20. Ravin HA. An improved colorimetric assay for ceruloplasmin. J Lab Clin Med 1961; 58: 161-8
21. Broman L. Separation and characterisation of two caeruloplasmins from human serum. Nature 1958; 182: 1655-7
22. Walshe JM. Penicillamine: treatment of first choice for patients with Wilson's disease. Mov Disord 1999; 14: 545-50
23. Huskisson EC. Side effects of penicillamine therapy in RA. J Rheumatol 1981; 8 (Suppl 7): 146-8
24. Sternlieb I, Fisher M, Scheinberg IH. Penicillamine-induced skin lesions. J Rheumatol 1981; 8 (Suppl 7): 149-54
25. Walshe JM. Penicillamine and the SLE syndrome. J Rheumatol 1981; 8 (Suppl 7): 155-60
26. Crawhall JC. Proteinuria in D-penicillamine-treated rheumatoid arthritis. J Rheumatol 1981; 8 (Suppl 7): 161-3
27. Camp AV. Haematological toxicity from penicillamine in rheumatoid arthritis. J Rheumatol 1981; 8 (Suppl 7): 164-8
28. Dawkins RL, Garlepp MJ, Macdonald BL, Williamson J, Zilo PJ, Carrano J. Myasthenia gravis and D-penicillamine. J Rheumatol 1981; 8 (Suppl 7): 169-74
29. Yonetani L, Walshe JM. Surviving Wilson's disease. Clin Med 2001; 1: 72-4
30. Walshe JM. Treatment of Wilson's disease with trientine (triethylene tetramine dihydrochloride). Lancet 1982; 318: 643-7
31. Simon SR, Branda RF, Tindle BH, Burns SL. Copper deficiency and sideroblastic anaemia associated with zinc ingestion. Am J Hematol 1988; 28: 181-3
32. Walshe JM. Tetrathiomolybdate as an anti-copper agent in man. In: Scheinberg IH, Walshe JM, eds. Orphan Diseases and Orphan Drugs. Manchester: Manchester University Press, 1986
33. Harper PL, Walshe JM. Reversible pancytopenia secondary to treatment with tetrathiomolybdate. Br J Haematol 1986; 64: 852-3
34. Spence JA, Suttle NF, Wenham G, El-Gallad T, Bremner I. A sequential study of the skeletal abnormalities which develop in rats given a small dietary supplement of ammonium tetrathiomolybdate. J Comp Pathol 1979; 89: 495-514
35. Walshe JM. Malignancy in Wilson's disease. Z Gastroenterol 2001; 39: 248 (abstract)